Number of the records: 1
Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition
- 1.
SYSNO ASEP 0534655 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition Author(s) Raninga, P. (AU)
Lee, A. (TW)
Sinha, D. (AU)
Dong, L.F. (AU)
Datta, K. (AU)
Lu, X. (AU)
Kalita-de Croft, P. (AU)
Dutt, M. (AU)
Hill, M. M. (AU)
Pouliot, N. M. (AU)
Gowda, H. (AU)
Kalimutho, M. (AU)
Neužil, Jiří (BTO-N) RID
Khanna, K. K. (AU)Number of authors 14 Source Title Theranostics. - : Ivyspring International Publisher - ISSN 1838-7640
Roč. 10, č. 12 (2020), s. 5259-5275Number of pages 17 s. Language eng - English Country AU - Australia Keywords stem-cell ; multiple-myeloma ; single-agent ; phase-ii ; bortezomib Subject RIV FP - Other Medical Disciplines OECD category 3.1 Basic medicine R&D Projects NV17-30138A GA MZd - Ministry of Health (MZ) Method of publishing Open access Institutional support BTO-N - RVO:86652036 UT WOS 000526083000007 EID SCOPUS 85084327191 DOI 10.7150/thno.42705 Annotation Purpose: Lacking effective targeted therapies, triple-negative breast cancer (TNBCs) is highly aggressive and metastatic disease, and remains clinically challenging breast cancer subtype to treat. Despite the survival dependency on the proteasome pathway genes, FDA-approved proteasome inhibitors induced minimal clinical response in breast cancer patients due to weak proteasome inhibition. Hence, developing effective targeted therapy using potent proteasome inhibitor is required. Workplace Institute of Biotechnology Contact Monika Kopřivová, Monika.Koprivova@ibt.cas.cz, Tel.: 325 873 700 Year of Publishing 2021 Electronic address https://www.thno.org/v10p5259.htm
Number of the records: 1